$IONS 0.44 Noisy

Notable posts

• @wallstengine bearish 41 eng

  $ALNY shares are moving higher after the $IONS/$AZN CARDIO-TTRansform Phase 3 trial in ATTR-CM missed its primary endpoint. Wainua/eplontersen did not significantly reduce CV mortality and recurrent CV events vs placebo through Week 140. Ionis said most patients were on stabilizers, with 57% on them at baseline and another 24% starting during the trial The monotherapy subgroup showed a nominally significant benefit, but patients already on stabilizers saw no treatment effect

  view on X →
• @TENETTRADEGROUP neutral 23 eng

  Tenet Pre-Market Movers July.09.26 $AEHR $ALNY $AP $SMPL $FCEL $AZZ $ASX $SNDK $GLSI $MARA $MU $BYRN $CBRS $AMAT $CECO $RMBS $BE $AMD $ENPH $IONS $RXT $MDA $AZN $LEVI $RDY $IBM $PLTR $META $PEP @ripster47 | @tenet_research | @TenetCharts https://t.co/koX2y94Wq9

  view on X →